Patent Foramen Ovale: PFO, Incidental Findings and Selected Closure

Direct answer. A patent foramen ovale, or PFO, is a persisting fetal flap route between the atria. It differs from an atrial septal defect and is often an incidental finding requiring no treatment. Finding a PFO after a stroke does not prove that it caused the event. Confidence is high in these distinctions. Selected patients may be assessed for closure after a full stroke and cardiac evaluation, but no device ranking or independently cleared numerical benefit is established here. AHA patent foramen ovale distinction, July2026; Leeds adult PFO procedure and selection context, June2025.

Evidence summary

Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.

What it is

Before birth, the foramen ovale permits an atrial route within the fetal circulation. After birth the flap usually closes against the septum. If that route remains patent, it is called a PFO. This history is different from a hole created by missing atrial septal tissue. Precise names matter because different structural findings have different clinical effects and treatment questions. AHA patent foramen ovale distinction, July2026.

A PFO can be discovered during imaging for an unrelated problem. A positive finding should be recorded accurately without automatically assigning symptoms or illness to it. A person can have both an incidental PFO and another cause of chest symptoms, palpitations or stroke. Those possibilities require their own assessment rather than a single finding becoming an explanation for everything. Leeds adult PFO procedure and selection context, June2025.

How it works

The flap can permit blood to cross under particular conditions. A clot entering the venous circulation could, in some circumstances, cross into the systemic arterial route instead of following the usual pulmonary route. That possible pathway is termed paradoxical embolism. Establishing a plausible mechanism is different from proving that it caused a particular clinical event. Leeds adult PFO procedure and selection context, June2025.

A stroke evaluation needs the actual event and alternative explanations. Arterial disease and rhythm-related sources can be relevant; finding a PFO does not exclude them. The responsible neurological and cardiac teams should explain what investigations have found, what remains uncertain and why the PFO is or is not considered pertinent to a secondary-prevention plan. Leeds adult PFO procedure and selection context, June2025; NHLBI arrhythmia diagnosis.

Imaging can describe the atrial route, associated anatomy and possible crossing. A selected contrast study or transoesophageal study answers a defined question. A home oxygen monitor, pulse reading or symptom list cannot diagnose a PFO or attribute a stroke to it. Interpretation should incorporate the reason for the test, its findings and the rest of the evaluation. NHLBI congenital investigation education, March2022.

In complex congenital circulation, an atrial communication can have a necessary physiological purpose. Consequently, “close every hole” is not a safe general rule. The AHA PFO education describes this anatomical distinction; it does not supply a full operative algorithm. The team must assess the whole circulation before a communication is altered. AHA patent foramen ovale distinction, July2026; NHLBI congenital procedure background, March2022.

The evidence-based treatments

Most incidental PFOs require no specific intervention. Management should first establish whether there is an actual clinical indication, rather than treat an imaging finding solely because it is present. Advice for an atrial septal defect, a cyanotic newborn or a person with a confirmed stroke mechanism cannot be transferred to every PFO. AHA patent foramen ovale distinction, July2026.

After stroke, selected closure assessment can form part of clinical care. It should include evaluation of alternative causes, suitability, medical treatment and the person’s preferences. The actual provider source is attributed clinical context; its outcome comparisons are excluded from the independent efficacy verdict because original device-trial and author financial chains remain unresolved. This does not instruct a patient to abandon a specialist recommendation. Leeds adult PFO procedure and selection context, June2025.

Catheter closure places an occluding device across the selected atrial route under imaging guidance. The procedure has a structural purpose; it does not eliminate every possible future stroke mechanism. Detailed consent should explain the exact intervention and patient-specific risks. A simplified explanation of a button-like device does not establish that a particular model is superior. Leeds adult PFO procedure and selection context, June2025.

Procedural injury, bleeding, infection, device problems and other adverse events belong in the decision. Numerical local complication rates are not reproduced here as personal predictions or independently verified evidence. The intended structural result, any change in clinical recurrence and longer-term harms are separate outcomes, and all deserve discussion rather than judging treatment only from an image of closure. NHLBI congenital procedure background, March2022.

Medical secondary prevention and aftercare require a prescribed plan. Do not independently stop an anticoagulant before a procedure, begin lifelong aspirin or copy a fixed post-device duration from a hospital leaflet. Exact medicines, timing and follow-up depend on the clinical indication and responsible team. A technically completed closure does not replace evaluation of any new possible stroke symptoms. Leeds adult PFO procedure and selection context, June2025.

Supplement and lifestyle evidence

Maintain ordinary cardiovascular health and follow any event-specific prevention advice. A healthy diet, activity and tobacco avoidance address wider risk factors; they do not demonstrate that a flap has closed or determine the cause of a prior stroke. An incidental finding need not become a universal activity ban. Medicines, travel or work questions after an intervention should use the actual aftercare plan rather than a general internet deadline. NHLBI lifelong congenital follow-up, March2022.

No supplement is established here as a treatment for patent foramen ovale. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.

What works and what does not

Useful PFO care distinguishes a common anatomical finding from a demonstrated clinical problem. It states why closure is being considered, what uncertainty remains and what alternative causes or treatments matter. A closed route, improved reassurance, fewer recurrent clinical events and procedural safety are separate outcomes. A persuasive device illustration or a clinician recommendation does not make its underlying trial financially independent.

Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.

Risks and side effects

New facial weakness, arm weakness, speech difficulty or another abrupt neurological deficit requires emergency help, even if it resolves or a PFO was previously closed. Severe breathing difficulty, collapse or severe chest symptoms also needs urgent assessment. Do not wait for an elective cardiology appointment or assume that a known PFO explains a new emergency. Share relevant device and medicine details when possible. NHLBI stroke and TIA emergency symptoms, May2023; NHS congenital heart disease national guidance, December2025.

An incidental PFO is different from an urgent neurological event or procedural complication. The immediate safety task is to evaluate the actual illness rather than treat the anatomical label. After an intervention, use the team’s contact instructions for deterioration, bleeding or other concerns. This article does not offer a personal stroke recurrence estimate, a device ranking or a fixed recovery guarantee. NHLBI congenital procedure background, March2022.

Important interactions

If clot-prevention medicines are prescribed, clarify their exact indication and review supplements at the same time. Blood-thinning products can add harm without establishing that a PFO was the event’s cause. Before a procedure, obtain direct instructions from the responsible team rather than independently interrupting a prescription. Tell other clinicians about any implanted occluder and continuing medicines. NHLBI congenital procedure background, March2022.

Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.

Who needs assessment

Ask why imaging was undertaken, whether the finding is isolated and what clinical event needs explanation. Following stroke, ask which alternative causes were assessed and what supports a PFO-related mechanism in this case. A murmur, pulse irregularity or consumer monitor result cannot settle that relationship. The stroke diagnosis, atrial anatomy and reason for treatment should remain distinct in the medical record. NHLBI congenital investigation education, March2022.

A PFO alone does not provide an individual reproductive-risk assessment or determine a medication plan. Pregnancy discussions should consider the actual clinical history and prescriptions. Complex congenital anatomy requires its own specialist evaluation; a communication essential to that circulation should not be treated by a generic closure rule. NHLBI congenital pregnancy and medicine review, March2022.

Clinician-led use and follow-up

Follow-up should match the actual indication and intervention. Retain imaging, device and stroke-evaluation records, and ask which changes require earlier contact. A planned reassuring echocardiogram does not exclude every later neurological or rhythm event. Review medicines and ongoing risk-factor care with the responsible clinicians; an incidental PFO and a recently implanted device do not require identical schedules. NHLBI lifelong congenital follow-up, March2022.

This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.

Animal and in-vitro evidence

Animal and cellular studies of heart development can investigate mechanisms and candidate genes. They cannot establish a safe human supplement regimen, prove that a structural defect will close, or select an operation for a child or adult. Models may differ substantially from a person’s congenital anatomy and circulation. No animal or in-vitro result contributes to the independent clinical verdict in this guide.

Funding and source roles

Financial interests include specialist imaging, genomic testing, pediatric and adult congenital services, medicines, occluders, conduits and valve implants. Institutional public funding does not clear individual research sponsors. The actual funding routes and unresolved author/trial chain are shown source by source. Manufacturer or materially conflicted clinical outcomes do not determine this article’s independent verdict.

The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.

Frequently asked questions

Is the fetal foramen ovale an abnormality before birth? No. It has a normal fetal role. AHA patent foramen ovale distinction, July2026.

Is a PFO an atrial septal defect? No. A persisting flap route and a tissue defect are distinct. AHA patent foramen ovale distinction, July2026.

Does a PFO found after stroke prove the cause? No. The rest of the evaluation matters. Leeds adult PFO procedure and selection context, June2025.

Does closure guarantee no future stroke? No. Other mechanisms and risks remain possible. Leeds adult PFO procedure and selection context, June2025.

Sources and funding notes

• NHLBI congenital heart defects overview, March2022 — Broader congenital structural context.
• NHLBI congenital investigation education, March2022 — Selected imaging roles, not a PFO self-screen.
• NHLBI congenital procedure background, March2022 — Procedure and medication background.
• NHLBI lifelong congenital follow-up, March2022 — General follow-up and health context.
• NHLBI congenital pregnancy and medicine review, March2022 — Clinical medication and reproductive review.
• NHS congenital heart disease national guidance, December2025 — Major deterioration and structural-disease emergency context.
• AHA patent foramen ovale distinction, July2026 — July2026 fetal flap, ASD distinction and mostly incidental finding, C-provisional.
• Leeds adult PFO procedure and selection context, June2025 — June2025 original adult procedure/causal uncertainty context; outcome claims, numerical rates and fixed regimens excluded.
• NHLBI arrhythmia diagnosis — Possible alternative electrical findings require recording.
• AHA original2025 congenital patient messages — Specialist coordination messages, C-provisional.
• NHLBI arrhythmias — Additional original linked in condition-specific education or follow-up.
• NHLBI stroke and TIA emergency symptoms, May2023 — Additional original linked in condition-specific education or follow-up.
• NHLBI budget — Financial provenance only.
• NHLBI Gift Fund — Financial provenance only.
• NHS national website funding policy — Financial provenance only.
• Leeds Teaching Hospitals audited2025–26 accounts — Financial provenance only.
• Leeds2026 annual report publication and institution location — Financial provenance only.
• AHA2024–25 annual report and named corporate support — Financial provenance only.
• AHA National Center Dallas contact — Financial provenance only.

Original clinical pages and their relevant financial disclosures were opened. Actual December2025 AHA adult-congenital summaries and patient messages were read. The full2025 ACC/AHA/HRS/ISACHD/SCAI guideline, author-declaration chain and slide download were blocked and were not read. No complete guideline assessment or numeric intervention criterion is inferred from the summaries. AHA2024–25 institutional financial disclosures and Dallas contact were checked; joint-society finances and direct page allocation remain unresolved. Institutional corporate funding is not assumed to fund this particular document. These summaries are attributed C-provisional clinical context, excluded from the independent efficacy verdict. Leeds Teaching Hospitals2025–26 original audited accounts were read separately from national NHS policy. Clinical leaflet review dates are source-specific and do not establish that every cited study was updated. Local procedure rates, fixed antithrombotic doses and recovery promises are not imported as independent evidence or personal instructions. Public clinical sources concentrate on US and English services; referral and treatment availability vary by jurisdiction. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.

Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.